Tvardi Therapeutics, Inc. (TVRD): auditor change — Tvardi completes merger with Cara, switches auditor to Deloitte, cash into 2H 2026

Tvardi Therapeutics, Inc.

Completed merger with Cara Therapeutics; received ~$23.8M net cash; cash runway expected into 2H 2026.
Dismissed Ernst & Young as auditor; engaged Deloitte & Touche for FY 2025; no disagreements reported.
Phase 2 data for TTI-101 in IPF expected 2H 2025; IND for TTI-109 planned 1H 2025.
Phase 1 study of TTI-101 in advanced solid tumors published in Clinical Cancer Research.

item 2.02 item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Tvardi Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: Deloitte & Touche LLP

Exact text from the filing

ismissal of Independent Registered Public Accounting Firm On May 12, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company dismissed Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm, with such dismissal to become effective immediately

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Tvardi Therapeutics, Inc. engaged Deloitte & Touche LLP as its auditor.

Action: engagement
Auditor: Deloitte & Touche LLP

Exact text from the filing

On May 13, 2025, Deloitte was engaged as the Company’s independent registered public accounting firm

View on SEC.gov

Browse all auditor changes →

Tvardi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-047856

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.